Sirolimus in kidney transplantation from marginal donors

F. Pisani, O. Buonomo, G. Iaria, B. Iorio, A. Rizzello, S. Pollicita, L. De Luca, M. Valeri, V. Boffo, A. Famulari, C. U. Casciani

Research output: Contribution to journalArticle


Nephrotoxicity caused by calcineurin inhibitors can lead to either delayed graft function or long-term decline of renal function after kidney transplantation. Therefore, recipients of renal transplants from marginal donors require non-nephrotoxic immunosuppression. Eighteen patients received kidney transplants from marginal donors, with a calcineurin inhibitor-free immunosuppressive regimen, based on basiliximab, mycophenolate mofetil, steroids, and sirolimus. Renal graft biopsy was performed in all cases before surgery. Mean follow-up was 11.8 months. We report immediate renal function in 9 patients, delayed graft function in 5 and acute tubular necrosis in 4 patients. One patient was successfully treated for biopsy-proven acute rejection. Hypercholesterolemia and hypertriglyceridemia were the most common adverse effects (n = 13) associated with arthralgia (n = 2) and thrombocytopenia (n = 2). Five patients underwent a switch to tacrolimus, due to sirolimus-induced side effects. Immunosuppression without the use of calcineurin inhibitors is a safe and effective regimen in kidney transplantation, although sirolimus-related side effects still represent a morbidity factor in these patients.

Original languageEnglish
Pages (from-to)495-496
Number of pages2
JournalTransplantation Proceedings
Issue number3
Publication statusPublished - Apr 2004

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Fingerprint Dive into the research topics of 'Sirolimus in kidney transplantation from marginal donors'. Together they form a unique fingerprint.

  • Cite this

    Pisani, F., Buonomo, O., Iaria, G., Iorio, B., Rizzello, A., Pollicita, S., De Luca, L., Valeri, M., Boffo, V., Famulari, A., & Casciani, C. U. (2004). Sirolimus in kidney transplantation from marginal donors. Transplantation Proceedings, 36(3), 495-496.